Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
Metrics: PDF 486 views | ?
1The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
2Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
3Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA
Published: May 10, 2023
Copyright: © 2023 Rao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has an addendum: Informed patient consent was obtained.
Original article: Oncotarget. 2019; 10:6038-6042. DOI: https://doi.org/10.18632/oncotarget.27203.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.